BioNTech SE (NASDAQ:BNTX) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA lowered its stake in shares of BioNTech SE (NASDAQ:BNTX) by 4.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,295,817 shares of the company’s stock after selling 220,701 shares during the quarter. Primecap Management Co. CA owned approximately 1.79% of BioNTech worth $489,508,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BNTX. GSA Capital Partners LLP acquired a new stake in BioNTech during the third quarter worth approximately $373,000. Victory Capital Management Inc. acquired a new stake in BioNTech during the third quarter worth approximately $345,000. OneDigital Investment Advisors LLC acquired a new stake in BioNTech during the third quarter worth approximately $361,000. Chesapeake Capital Corp IL acquired a new stake in BioNTech during the third quarter worth approximately $442,000. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in BioNTech during the third quarter worth approximately $1,125,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BNTX. Canaccord Genuity Group restated a “buy” rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $150.00 target price on shares of BioNTech in a research report on Monday, November 18th. Berenberg Bank began coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price on the stock. Morgan Stanley lowered their target price on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 11th. Finally, Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $143.73.

BioNTech Stock Up 1.4 %

BNTX opened at $100.86 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The stock has a market capitalization of $24.18 billion, a price-to-earnings ratio of -48.03 and a beta of 0.30. The business has a 50-day moving average of $115.11 and a two-hundred day moving average of $113.46.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the prior year, the business earned $1.90 EPS. BioNTech’s quarterly revenue was down 19.5% compared to the same quarter last year. On average, research analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.